The current financial score of RenovoRx Inc is 7.68. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 909.00K, representing a year-over-year increase of 115.40%, while its net profit experienced a year-over-year increase of 0.55%.
The current valuation score of RenovoRx Inc is 7.70. Its current P/E ratio is -4.92, which is -86.83% below the recent high of -0.65 and -54.60% above the recent low of -7.60.
The current earnings forecast score of RenovoRx Inc is 8.00. The average price target is 7.12, with a high of 14.50 and a low of 3.00.
The current price momentum score of RenovoRx Inc is 5.92. Currently, the stock price is trading between the resistance level at 2.35 and the support level at 1.15, making it suitable for range-bound swing trading.
The current institutional shareholding score of RenovoRx Inc is 3.00. The latest institutional shareholding proportion is 20.02%, representing a quarter-over-quarter decrease of 0.19%. The largest institutional shareholder is James Simons, holding a total of 11.40K shares, representing 0.00% of shares outstanding, with 63.41% decrease in holdings.
The current risk assessment score of RenovoRx Inc is 2.49. The company's beta value is 1.03. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.